TWO · 4743.TWO
Oneness Biotech Co., Ltd.
NT$45.80-NT$1.20 (-2.55%)
Oneness Biotech Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 40.29% below the high.
Loading market information…
TWO · 4128.TWO · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Microbio Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 38.38% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Microbio Co., Ltd.’s forward annual dividend is NT$0.04 per share, paid annual. The forward yield is 0.28% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Microbio Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Microbio Co., Ltd., established in 2000 and headquartered in Taipei, Taiwan, functions as a comprehensive biotechnology enterprise. The company's core activities involve the research, development, manufacturing, and commercialization of advanced biopharmaceutical drugs and nutritional supplements within Taiwan. Currently, Microbio offers two key products: MS-20, designed to alleviate fatigue and appetite loss experienced by cancer patients undergoing chemotherapy, and Herbiron, aimed at addressing symptoms linked to iron deficiency anemia and menstrual discomfort. Its robust drug pipeline includes several compounds in various stages of development. In the preclinical phase, the company is developing SNA-03 and SNA-07 for cancer immunotherapy, SNP-630 for non-alcoholic steatohepatitis (NASH), FB918 targeting non-allergic eosinophilic asthma, and SNS812 as an investigational treatment for Cov-flu. Moving into Phase I clinical trials, Microbio is advancing OB-318 as an anti-cancer agent, MB-110 for hepatitis C therapy, SNP-810 as an acetaminophen alternative, FB317 for moderate-to-severe allergic asthma and chronic idiopathic urticaria, and FB704A, which is being explored for conditions like rheumatoid arthritis, certain cancers, and cytokine storms. Furthermore, FB825 is currently undergoing Phase II clinical assessment for its potential in treating atopic dermatitis, allergic asthma, hyper IgE syndrome, and various food allergies. In its late-stage development, Microbio has two products in Phase III trials: ON101, designed to treat diabetic foot ulcers, and MB-6, an adjuvant therapy for metastatic colorectal cancer. The discovery pipeline holds additional candidates such as FB121 for AIDS, SNA01 for PD-1 related cancers, SNA02 for cancer immunotherapy, and SNS01 targeting recurrent metastatic non-small cell lung cancer. Additionally, Microbio is developing SNP-830 and SNP-840, novel analgesics designed to be free from hepatotoxicity. Beyond pharmaceuticals, Microbio diversifies its operations through organic food trading, beverage sales, technology development and transfer services, consulting, and even magazine publishing.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:54 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$45.80-NT$1.20 (-2.55%)
Oneness Biotech Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 40.29% below the high.
NT$79.90-NT$0.50 (-0.62%)
TTY Biopharm Company Limited’s quoted price sits in the upper half of its reported 52-week range, 8.16% below the high.
NT$133.50+NT$0.50 (+0.38%)
AP Biosciences Inc’s quoted price sits in the lower half of its reported 52-week range, 43.43% below the high.
NT$58.20+NT$1.50 (+2.65%)
PharmaEngine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 21.77% below the high.
NT$45.40-NT$3.10 (-6.39%)
OBI Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.04% below the high.
NT$8.37-NT$0.31 (-3.57%)
TaiGen Biopharmaceuticals Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 48.96% below the high.
NT$17.90-NT$0.10 (-0.56%)
TWi Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.71% below the high.
NT$54.00-NT$1.70 (-3.05%)
Sinew Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.47% below the high.
